Sotorasib.
Författaruppgift saknas
Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxab253 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för sotorasib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
23 hitsSotorasib: First Approval.
Blair HA.
Drugs · review-article; review; journal article · DOI 10.1007/s40265-021-01574-2Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells.
Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13153906Sotorasib effective in KRAS-mutant NSCLC.
Sidaway P.
Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/s41571-021-00533-wLentiviral-Driven Discovery of Cancer Drug Resistance Mutations.
Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R.
Cancer Res · brief-report; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-21-1153Virtual clinical trial simulations for a novel KRAS<sup>G12C</sup> inhibitor (ASP2453) in non-small cell lung cancer.
Sayama H, Marcantonio D, Nagashima T, Shimazaki M, Minematsu T, Apgar JF, Burke JM, Wille L, Nagasaka Y, Kirouac DC.
CPT Pharmacometrics Syst Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/psp4.12661FDA Approves First KRAS Inhibitor: Sotorasib.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-nb2021-0362Sotorasib Is Active in <i>KRAS</i> <sup>G12C</sup>-Mutant Non-Small Cell Lung Cancer.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-rw2021-086Nonclinical Safety Profile of Sotorasib, a KRAS<sup>G12C</sup>-Specific Covalent Inhibitor for the Treatment of <i>KRAS p.G12C</i>-Mutated Cancer.
Ishida K, Werner JA, Davies R, Fan F, Thomas B, Wahlstrom J, Lipford JR, Monticello T.
Int J Toxicol · research support, non-u.s. gov't; journal article · DOI 10.1177/10915818211022965Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation.
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R.
N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa2103695Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
Kitazawa M, Miyagawa Y, Koyama M, Nakamura S, Hondo N, Miyazaki S, Muranaka F, Tokumaru S, Yamamoto Y, Ehara T, Kuroiwa M, Tanaka H, Komatsu D, Takeoka M, Soejima Y.
Mol Clin Oncol · research-article; journal article · DOI 10.3892/mco.2021.2310Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS<sup>G12C</sup>, are associated with renal toxicity in the Sprague Dawley rat.
Werner JA, Davies R, Wahlstrom J, Dahal UP, Jiang M, Stauber J, David B, Siska W, Thomas B, Ishida K, Humphreys WG, Lipford JR, Monticello TM.
Toxicol Appl Pharmacol · journal article · DOI 10.1016/j.taap.2021.115578KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, Chiba M, Shimoji M, Takemoto T, Arita T, Gmachl M, Hofmann MH, Soh J, Mitsudomi T.
J Thorac Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jtho.2021.04.015Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Retmana IA, Loos NHC, Schinkel AH, Beijnen JH, Sparidans RW.
J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2021.122718Sotorasib Edges Closer to Approval.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2021-0309Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice.
Madhyastha N, Samantha SK, Dittakavi S, Markose M, Mallurwar SR, Zainuddin M, Mullangi R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.5043Mechanisms of Resistance to KRAS<sup>G12C</sup> Inhibitors.
Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers13010151KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT.
N Engl J Med · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1917239KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations.
Pantsar T.
Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-020-68950-yAMG 510 Shows Activity beyond NSCLC.
Författaruppgift saknas
Cancer Discov · comment; news · DOI 10.1158/2159-8290.cd-nb2020-061Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors.
Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang HL, Wurz RP, Xue M, Yang KC, Achanta P, Bartberger MD, Canon J, Hollis LS, McCarter JD, Mohr C, Rex K, Saiki AY, San Miguel T, Volak LP, Wang KH, Whittington DA, Zech SG, Lipford JR, Cee VJ.
J Med Chem · research support, non-u.s. gov't; news; research support, u.s. gov't, non-p.h.s.; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.9b01180The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR.
Nature · clinical trial; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41586-019-1694-1AMG 510 First to Inhibit "Undruggable" KRAS.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2019-073